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Background: Randomized controlled trials have shown that periprocedural rates of stroke and death are higher with
carotid artery stenting (CAS) than with carotid endarterectomy (CEA) in the treatment of carotid artery stenosis.
Diffusion-weightedmagnetic resonance imaging (DW-MRI) has shown higher rates of clinically silent new ischemic brain
lesions when CAS is performed as compared with CEA. The Silk Road Medical Embolic PROtectiOn System:
First-In-Man (PROOF) Study is a single-arm first-in-man study using the MICHI Neuroprotection System (Silk Road
Medical Inc, Sunnyvale, Calif), a novel transcervical access and cerebral embolic protection system. This system enables
stent implantation under controlled blood flow reversal of the carotid artery, also known as Flow Altered Short
Transcervical Carotid Artery Stenting (FAST-CAS).
Methods: Between March 2009 and February 2010, a total of 44 subjects were enrolled into the study. The primary
composite endpoint was major stroke, myocardial infarction, or death within 30 days. Forty-three patients (97.7%)
completed the study through the 30-day endpoint. One patient was lost to follow-up. In a subgroup of consecutive
subjects, DW-MRI examinations were performed preprocedure and within 24 to 48 hours after the stent implantation.
Blinded independent neuroradiologists reviewed all DW-MRI studies and confirmed the absence or presence of new
ischemic brain lesions.
Results: All enrolled patients were successfully treated, and no major adverse events were seen through the follow-up
period. Thirty-one subjects had DW-MRI examinations. Of these, five patients (16%) had evidence of new ischemic brain
lesions but no clinical sequelae. Transient intolerance to reverse flow was reported in 9% of cases, but in all cases, a stent
was successfully placed, and the intolerance was managed by minimizing the duration of reverse flow during the
procedure.
Conclusion: In this first-in-man experience, FAST-CAS using theMICHINeuroprotection System was shown to be a safe
and feasible method for carotid revascularization. DW-MRI findings suggest controlled reverse flow provides cerebral
embolic protection similar to that seen with CEA. (J Vasc Surg 2011;54:1317-23.)
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iCarotid artery stenosis is associated with increased
stroke risk and has been commonly treated with atheroscle-
rotic risk factor modification and interventions, which in-
clude carotid artery stenting (CAS) and carotid endarterec-
tomy (CEA). Large-scale trials established a role for CEA in
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doi:10.1016/j.jvs.2011.04.040educing long-term stroke risk and established the American
eart Association/American Stroke Association (AHA/
SA) and the European Society for Vascular Surgery (ESVS)
uidelines for treatment of occlusive carotid artery dis-
ase.1,2 CAS has more recently been developed, and several
anufacturers’ systems have been approved for use. How-
ver, several multicenter randomized trials reported that
eath and stroke rates with CAS were higher than with
EA, and CAS has not been as widely accepted as CEA for
reatment of occlusive carotid artery disease.3,4
The Carotid Revascularization Endarterectomy vs
tenting Trial (CREST) study5 was a multicenter National
nstitutes of Health-sponsored randomized controlled trial
hat showed higher rates of periprocedural stroke and death
n the CAS arm as compared with the CEA arm (4.4% CAS
s 2.3% CEA; P  .005). In contrast, the CAS rate for
yocardial infarction (MI) was lower than the CEA rate
1.1% CAS vs 2.3% CEA; P  .03). The International
arotid Stenting Study (ICSS) trial6 was a European multi-
enter randomized controlled trial in symptomatic patients
hat found CEA to be statistically superior to CAS in the
ncidence of stroke, death, or periprocedural MI at 120
ays (5.2% CEA vs 8.5% CAS; P  .006).
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November 20111318 Pinter et alDiffusion-weightedmagnetic resonance imaging (DW-
MRI) is a diagnostic tool used to detect cerebral embolic
events that are associated with diagnostic and therapeutic
procedures.7 A systematic review of carotid revasculariza-
tion studies by Schnaudigel et al8 involving 1363 CAS and
754 CEA procedures suggested evidence of new brain
lesions as measured by DW-MRI at rates of 37% and 10%
(P  .01), respectively.
TheMICHINeuroprotection System (Silk RoadMed-
ical, Inc, Sunnyvale, Calif) employs controlled reverse flow
with a transcervical approach and is designed to provide a
shorter, more direct route for delivery of angioplasty bal-
loons and stents than the traditional transfemoral route.
The design of the MICHI system evolves the neuroprotec-
tive reverse flow concept first developed by Juan Parodi9 by
allowing the operator to regulate from a low, baseline level
of reversed flow to a higher reverse flow rate, which mimics
the back-bleeding step utilized during CEA. The transcer-
vical access approach avoids catheter manipulation in the
aortic arch, supra-aortic vessels, and common carotid artery
(CCA), steps which may liberate atherosclerotic plaque
debris into the brain.10 The purpose of the Silk Road
Medical Embolic PROtectiOn System: First-In-Man
(PROOF) Study was to determine if FAST-CAS using the
MICHI system enables safe, controlled reverse flow of the
carotid artery and is compatible with the techniques, de-
vices, and equipment used during CAS procedures.
METHODS
Study design. The PROOF study is a prospective
single-center trial with a sample size of up to 65 subjects to
allow for a reasonable assessment of safety. This study was
reviewed and approved by an independent ethics commit-
tee, and all patients gave informed consent prior to enroll-
ment. Data were prospectively collected regarding medical
history, neurological status, symptomatic status, degree of
carotid stenosis, and procedural adverse events, in addition
to major adverse events within 30 days of the procedure.
Subjects were offered entry into the study if they had a
lesion located in the internal carotid artery (ICA; the ca-
rotid bifurcation could be involved) and had a minimum
distance of 5 cm between the clavicle and carotid bifurca-
tion as assessed by duplex Doppler ultrasound, computed
axial tomographic angiography (CTA), or magnetic reso-
nance angiography (MRA). Exclusions included: participa-
tion in another investigational trial; dementia or neurolog-
ical illness that may confound the neurological evaluation;
evidence of stroke within the previous 30 days of the
procedure; history of intracranial hemorrhage within the
previous 3 months, including hemorrhagic transformation
of an ischemic stroke; total occlusion of the target vessel;
previously placed stent in the target artery; or atheroscle-
rotic disease involving the ipsilateral CCA that precluded
safe placement of the arterial sheath.
Device description and use. The MICHI Neuropro-
tection System consists of an 8-F transcervical arterial access
sheath with a large-bore Y-arm adapter, a large-bore blood
flow line with a flow controller, and an 8-F venous return (heath. The reverse flow circuit is completed by connecting
he arterial sheath and the venous sheath with the large-
ore flow line (Fig 1, A). The system’s design allows the
ircuit to drape down the patient’s thorax and abdomen
nd allows a single interventionist to work between mid-
hest and midabdomen away from the x-ray source and
mage intensifier.
The reverse flow circuit is designed to prevent micro-
nd macroemboli from reaching the brain by means of flow
eversal in the internal carotid artery. Reverse flow is
chieved through establishment of an arteriovenous (AV)
hunt between the CCA and the femoral vein (FV) together
ith occlusion of the proximal CCA. The system has the
bility to shift between high- and low-flow reversal rates via
toggle switch on the flow controller. This toggle diverts
he shunt flow between a low resistance path, enabling a
igher flow rate, to a higher resistance flow path, resulting
n a lower shunt flow rate. Additionally, the flow controller
as a flow stop button that allows cessation of reverse flow
uring procedural maneuvers such as contrast injections
ig 1. The MICHI Neuroprotection System. A, The system
onsists of a transcervical arterial access sheath, a shunt line with a
ow controller, and a femoral venous return sheath, forming an
rteriovenous shunt circuit (indicated in red). B,Detail of the flow
ontroller. A toggle switch allows shifting from “Lo” baseline flow
o “Hi” flow, at the operator’s discretion. The Flow Stop button
llows interruption of reverse flow for antegrade angiography
njections or at the operator’s discretion.see Fig 1, B).
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Volume 54, Number 5 Pinter et al 1319Study procedures and surgical technique. Neurological
examinations were conducted preprocedure. Mean arterial
blood pressure, transcutaneous oxygen saturation, and
neurological status were continuously monitored by an
anesthesiologist in all patients. Patient neurologic status
was additionally assessed during the procedure by the sur-
geon. The arterial sheath was placed directly in the CCA via
a surgical cut down through a low cervical mini-incision
(2 cm), and the venous sheath was placed percutaneously
in the right or left FV. Heparin was administered intrave-
nously after cut down, targeting an active clotting time
(ACT) 250 seconds. A Silastic vessel loop was placed
around the CCA (typically 1 minute after skin incision) to
control the carotid artery prior to puncture. A Z–stitch or
purse-string suture (5-0 or 6-0 Prolene, Ethicon, Somer-
ville, NJ) was placed at the anticipated CCA puncture site
for later arteriotomy closure. Arterial puncture and sheath
insertion were accomplished using a micropuncture cathe-
ter (Fig 2, A). After arterial access was obtained, the arterial
sheath was secured with forward-tensioning anchoring su-
tures at the skin. A beveled external sleeve on the body of
the sheath was used to prevent the tip of the arterial sheath
from advancing into the diseased segment. The circuit was
completed by connecting the arterial and venous sheaths
Fig 2. Placement of the reverse flow circuit.A, The arterial access
sheath is placed via a 2-cm incision above the clavicle into the
common carotid artery. B, The venous sheath is inserted percuta-
neously in the femoral vein and connected via the flow line to the
arterial sheath. The reverse flow circuit is established and con-
trolled by an interposed flow line with flow controller.with the flow line (Fig 2, B), thereby establishing the AV dhunt. Once the shunt was established, reverse flow was
nitiated by occlusion of the CCA using either a Silastic
essel loop, a vascular clamp, or a combination of the two.
Prior to introduction of guide wires and catheters
cross the target lesion, reverse flow in the shunt was
onfirmed for every patient by injecting a bolus of clear
aline in the shunt line and visualizing the bolus movement
rom the arterial to venous direction. Reverse flow in the
arotid arteries was also assessed angiographically. Inter-
entional devices were delivered and removed via a hemo-
tatic access port located on the proximal end of the arterial
ccess sheath. The CAS procedure was performed using
tandard techniques. The flow controller was set to high
everse flow during procedural maneuvers considered
igher risk for emboli generation, including lesion crossing
ith guidewires or catheters, stent deployment, balloon
ngioplasty, and release of the CCA occlusion. At all other
imes, the flow controller was set to low flow. This targeted
se of high reverse flow was developed to minimize the
otential of patient intolerance, although most patients
olerated extended periods of high reverse flow. At the end
f the procedure, hemostasis at the arteriotomy site was
chieved utilizing the previously placed sutures. After
heath removal and vessel closure, the CCA was observed
or any evidence of bleeding before skin closure.
Study endpoints. The primary safety endpoint of the
tudy was a composite of any major stroke, MI, and death
ithin 30 days. Stroke was defined as any sudden develop-
ent of focal neurological deficits usually related to im-
aired cerebral blood flow (thrombosis, hemorrhage, or
mbolism). Major stroke was defined as a stroke that was
resent after 7 days and increased the National Institute of
ealth Stroke Scale (NIHSS) of the subject by 4 points.
o ensure that neurological evaluations were conducted
nd evaluated consistently, the same physician (an indepen-
ent neuro-anesthesiologist) evaluated the subject both
re- and postprocedure. The physician was trained on the
equired neurological and cranial nerve assessments and
ould send the subject for further neurological evaluation if
stroke, transient ischemic attack (TIA), or cranial nerve
njury was suspected.
In order to obtain a more sensitive surrogate marker of
mbolic brain injury, DW-MRI was added as a substudy to
he protocol after approximately 25% of the subjects had
een enrolled. Upon protocol revision, scans were ob-
ained on all consecutive patients who were eligible for
agnetic resonance imaging. The DW-MRI scans were
cquired with sagittal T1 sequences, T2 W axial, fluid-
ttenuated inversion recovery (FLAIR) axial, and apparent
iffusion coefficient (ADC) map. In addition, T1 W axial
nd sagittal sequences were conducted after contrast ad-
inistration. DW-MRIs were conducted within 24 hours
efore and within 24 to 48 hours after the procedure. Pre-
nd postoperative DW-MRIs were read by two indepen-
ent neuroradiologists (BL and CL) at outside centers who
ere blinded to the timing (pre- or postoperative) of the
aired scans and who were unaware of the patients’ proce-
ural details or clinical status. Presence or absence of all
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November 20111320 Pinter et allesions in both cerebral hemispheres were recorded by each
reader and compared with that of the second reader. Dis-
crepancies were reviewed and reconciled.
RESULTS
Subject enrollment. All FAST-CAS cases were per-
formed at Augusta Hospital in Düsseldorf, Germany. Be-
tween March 2009 and February 2010, a total of 44
patients were enrolled. Patients were selected based on
protocol inclusion/exclusion criteria. No patients were ex-
cluded due to inadequate clavicle-to-bifurcation distance.
Subject population. The mean age of the study pop-
ulation was 71.4 years (range, 57-88 years). Twenty-eight
patients (64%) were men. Four patients (9.1%) had symp-
tomatic carotid artery stenosis; one with TIA, one with
amaurosis fugax, and two with a previous stroke. Table I
provides complete patient population data.
The anatomic and procedural characteristics were typ-
ical for patients with severe carotid artery disease, as shown
in Table II. Five patients had occlusion of the contralateral
ICA, and one patient had recurrent ICA stenosis after CEA.
The mean lesion length treated was 13.5 5.4 mm. Severe
calcification at the lesion was noted by the operating phy-
sician in 26 subjects (59.0%). CCA depth from the skin was
noted to be 1.5  0.8 cm, and the clavicle to carotid
bifurcation distance was 7.1  1.2 cm.
Procedural results. Procedural efficacy results are re-
ported in Table III. Of the 44 procedures where FAST-
CAS was attempted, the MICHI system was successfully
placed in 42. In two procedures, the arterial sheath could
not be placed through the arterial puncture. In both cases,
access to the common carotid artery was subsequently
obtained using a commercially available 8-F introducer
sheath, and the CAS procedure was completed with a distal
filter (FilterWire EZ; Boston Scientific Corporation,
Natick, Mass) in place of reverse flow embolic protection.
In one of these patients, it was noted that the CCA was
Table I. Baseline demographics and comorbid
conditions
Patient characteristics n  44
Gender (male) 28 (64%)
Age, years
Average (min, max) 71.4 (57, 88)
75 years of age 13 (29.5%)
Size
Weight, kg ( SD) 76  14
Height, cm ( SD) 169  8
Symptomatic 4 (9%)
Previous carotid endarterectomy 8 (18%)
Contralateral occlusion 5 (11%)
Diabetic 13 (29%)
Recent myocardial infarction 2 (5%)
Congestive heart failure 6 (14%)
Hyperlipidemia 14 (32%)
Decreased left ventricular ejection fraction 0 (0%)
History of angina 11 (25%)heavily calcified. The taper at the arterial sheath tip was pubsequently improved, and there were no further difficul-
ies reported with sheath insertion.
Of the 42 procedures where the MICHI system was
laced, the carotid stent intervention could not be com-
leted in two cases. In one case, there was inability to cross
he lesion with a guidewire. In the second case, there was
oncern over a small arterial dissection that was attributed
o the micropuncture step and not to the insertion of the
rterial sheath. Both cases were successfully converted to
EA immediately. Fig 3 provides details of patient recon-
iliation.
General anesthesia was used in one case where the
ubject became increasingly agitated during the FAST-CAS
rocedure. Local anesthesia was used in all other cases,
ncluding the two patients who converted to CEA.
Predilatation was performed with standard angioplasty
alloons on 11 of the 42 patients who completed a CAS
able II. Lesion location and vessel characteristics
rocedure characteristics n  44
esion location
Right 18 (41.0%)
Left 26 (59.0%)
ICA 27 (61.0%)
ICA and CCA 17 (39.0%)
reprocedure vessel characteristics n  40a
CA diameter, mm ( SD) 5.2  0.7
CA diameter, mm ( SD) 8.1  0.8
Stenosis, % ( SD) 87.6  6.4
esion length, mm ( SD) 13.5  5.4
Severely calcified 26 (59%)
Severe tortuosity 2 (5%)
lavicle to bifurcation, cm ( SD) 7.1  1.2
CCA depth, cm ( SD) 1.5  0.8
CA, Common carotid artery; ICA, internal carotid artery; SD, standard
eviation.
Includes only subjects who were successfully treated with the MICHI
europrotection System.
able III. Procedural efficacy results
fficacy Endpoints n  44
stablishment of silk road reverse flow circuit 42 (96%)
ime on reverse flow, min (mean  SD)a 18  12
ime on hi flow, min (mean  SD)a 11  7
ost procedure residual stenosis, % ( SD)b 7.6  9.8
olume of contrast used, cc ( SD)b 18.2  9.9
ocal anesthesia use 43 (98%)
olerance to reverse flow per protocolc 41 (100%)
nvestigator-reported transient intolderancec 4 (10%)
Includes data only for patients in whom reverse flow was established (n
2).
Includes data only for patients in whom a carotid artery stenting procedure
as completed (n  42).
Includes data only for patients in whom tolerance could be assessed
n  41).rocedure. A Carotid Wallstent Endoprosthesis (Boston
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Volume 54, Number 5 Pinter et al 1321Scientific Corporation; n  37) or Vascuflex Stent (B
Braun, Melsungen AG, Berlin, Germany; n  5) was im-
planted at the target lesion. Postdilatation was performed
on 36 patients.
Device efficacy. The MICHI Neuroprotection Sys-
tem was used to establish reverse flow in 42 subjects
(95.5%), including the two subjects who were later con-
verted to CEA. For these cases, the reverse flow time was a
median of 18 minutes, of which 11 minutes were on the
high-flow setting. Toggling between low- and high-reverse
flow states was done frequently during each procedure and
was imperceptible to the patient or monitoring anesthesi-
ologist. The short access length enabled a minimum
amount of contrast to be used during intraprocedural an-
giography (mean, 18.2 mL contrast volume).
Intolerance to reverse flow. Intolerance to reverse
flow was not assessed in three patients, including the two
patients with distal filters and one patient who converted to
CEA before reverse flow intolerance could be assessed.
Intolerance to reverse flow was assessed in all other patients
by the treating physician and was defined as the “inability to
complete the procedure with the reverse flow circuit in
either the high-flow or low-flow setting.” Using this pro-
tocol definition, all subjects where reverse flow was assessed
Fig 3. Patient enrollmenwere considered tolerant of reverse flow. OTransient intolerance was reported by the investigator
n four subjects (10% of assessed patients). In one case, the
atient lost the use of his contralateral arm. In the other
hree cases, intolerance manifested as a loss of conscious-
ess (LOC). Three of the four subjects with transient
ntolerance also had contralateral carotid occlusions. In
ach case, the intolerance was managed by minimizing the
uration of carotid occlusion and reverse flow. Preselection
nd preparation of balloons and stents after initial angiog-
aphy but prior to carotid occlusion and initiating flow
eversal minimized procedure times. In all instances, a stent
as implanted, and the symptoms of transient intolerance
esolved when antegrade flow was restored, with no resid-
al neurological deficit or permanent clinical sequelae.
Device safety. There were no major adverse events,
ncluding major stroke, death or MI, seen over the 30-day
ollow-up period. There was one late event, a minor contralat-
ral stroke,whichwas reportedat the30-day follow-upvisit.This
vent was reported in a subject that had a negative
W-MRI examination 5 days postprocedure and was
djudicated to be nonprocedure-related by the indepen-
ent Clinical Events Committee. There were no cranial
erve injuries detected on serial neurologic examinations.
procedure reconciliation.ne subject had a gastrointestinal bleed 2 days postproce-
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November 20111322 Pinter et aldure. The gastrointestinal bleed was not device related and
was a known complication of concomitant medications.
DW-MRI findings. Thirty-one consecutive subjects
received DW-MRI scans (Table IV). Five subjects had new
DW-MRI lesions post procedure (16.1%), with a total of 18
new DW-MRI lesions across all five patients.
DISCUSSION
Data from multiple randomized studies such as
CREST, ICSS, Endarterectomy versus Angioplasty in Pa-
tients with Symptomatic Severe Carotid Stenosis (EVA-
3S), and Stent-Supported Percutaneous Angioplasty of the
Carotid Artery versus Endarterectomy (SPACE) show that
CAS with transfemoral access and the use of distal filters are
limited by both technology and the technical skill required
of interventionists. The ICSS DW-MRI substudy saw 231
symptomatic patients (124 CAS and 107 CEA) undergo
DW-MRI pre- and postprocedure.11 Of the CAS patients,
50% had at least one new ischemic brain lesion posttreat-
ment, compared with just 17% of the CEA patients (P 
.0001). The new ischemic brain lesion rate in the CAS arm
was highest (73% of patients) in centers with a policy of
using embolic protection devices, and only distal filter-type
devices were used in ICSS. The review of carotid revascu-
larization literature presented by Schaudigel confirms this
trend, with DW-MRI rates of 37% and 10% for CAS and
CEA, respectively (P  .01).8 Of note, the incidence of
new ischemic brain lesions in the contralateral hemisphere
was markedly different between CEA (0.01%) and tradi-
tional CAS (14.5%; P .01), suggesting embolization into
the contralateral carotid artery stemming from guidewire
and catheter manipulation in the aortic arch. By similar
logic, a large proportion of ipsilateral lesions are also likely
due to aortic arch and proximal CCA manipulation inher-
ent to the transfemoral access route.
Transfemoral CAS with flow reversal is a method de-
veloped by Juan Parodi as an alternative to the use of distal
protection devices. Parodi et al reported that their system
did not consistently overcome external carotid artery
(ECA) to antegrade ICA flow with CCA occlusion alone
and thus incorporated an ECA occlusion element to ensure
Table IV. DW-MRI results (percentage of mITT
patients)
DW-MRI parameters All (n  31)a
Number of subjects with DW-MRI lesion(s)
pre- and postprocedure 1 (3.2%)
Number of subjects with new DW-MRI lesion(s)
postprocedure 5 (16.1%)
Total number of new DW-MRI lesion(s)
postprocedure 18
Number of new DW-MRI lesion(s) per subject
postprocedure (min, max) 3.6 (2, 9)
DW-MRI, Diffusion-weighted magnetic resonance imaging; mITT, modi-
fied intent to treat.
aIncludes all subjects with DW-MRI data.reversal of flow in the ICA.9 While novel in its approach, chis method still requires unprotected delivery of a catheter
ystem from the femoral artery to the CCA and a balloon
cclusion device in the ECA, thus creating a potential for
ascular trauma and embolic consequence. Parodi et al also
eported a significant reduction in flow when a stent de-
loyment device was introduced into the balloon sheath,
oinciding with one of highest-risk moments for embolic
ebris generation. Many users of the Parodi system report
dding a syringe aspiration step, as recommended in the
anufacturer’s Instructions for Use,12 during any direct
nteraction with the lesion.
Chang et al13 and Criado et al14 developed a derivative
echnique that combines carotid flow reversal and direct
ccess of the CCA. This transcervical approach avoids the
mbolic risk of traversing the aortic arch and supra-aortic
asculature, especially desirable in patients with severe ca-
otid tortuosity and difficult aortic arch anatomy. Several
ingle-center clinical series suggest that transcervical access
ith flow reversal is an effective approach, demonstrating
troke and death rates similar to CEA,15-17 and transcranial
oppler (TCD) measurements showing a cross-clamp-like
bsence of microembolic signals.18
The system studied in this report evolves these flow
eversal concepts further. The Chang and Criado approach
equires flow to traverse from artery to vein through the
igh-resistance sidearm connectors of arterial and venous
heaths, which limit the rate of reverse flow. The design of
he MICHI Neuroprotection System offers a lower resis-
ance shunt between arterial and venous circulations, with
he ability to switch between a low, baseline reverse flow
ate to a higher flow rate. This higher flow rate obviates the
eed to occlude the ECA and may also reduce or eliminate
he need for an active aspiration step. The flow stop and
igh-/low-flow push buttons enables the interventionist to
alance patient tolerance needs with optimal neuroprotec-
ion during periods of the procedure that are at highest risk
or liberation of embolic debris (eg, angiography, angio-
lasty, stent placement).
This initial experience with the MICHI Neuroprotec-
ion System has enabled refinement of patient selection and
rocedural techniques for the FAST-CAS procedure. The
ontribution of the highly calcified carotid artery toward
ne of the failed arterial sheath insertion cases highlights
he importance of prescreening the common carotid artery
or suitability of direct cervical access. The procedural ma-
euvers developed to address transient intolerance, espe-
ially important in patients with contralateral carotid occlu-
ions, highlight the importance of device preparation and
he benefits of FAST-CAS as a relatively short procedure
the mean procedure time from the start of cut down to
nal closure of the arteriotomy was 36 minutes [range, 14
inutes to 1 hour 17 minutes]). Switching from high to
ow reverse flow, pressing the flow stop button, or un-
lamping the CCA and restoring antegrade flow are addi-
ional intolerance management strategies. In addition, the
wo cases that converted to CAS with a distal filter demon-
trate the ability of the FAST-CAS procedure to safely
onvert to filter-protected transcervical CAS. Converting
11
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Volume 54, Number 5 Pinter et al 1323FAST-CAS to CEA is also possible. In the two cases in this
series that converted to CEA, the patient was converted to
general anesthesia in the same room, and the cervical skin
incision used to gain direct carotid arterial access was simply
extended to expose the carotid bifurcation.
The direct access approach to the carotid artery utilized
in the FAST-CAS procedure appears to be readily adopt-
able by the CEA-trained vascular surgeon. The primary
operator (LP) was able to consistently gain rapid access to
the CCA after only one to two cases of experience, and
stent placement was similarly straightforward given the
short distance from access site to the target lesion. Secure
closure was achieved in all patients by means of the pre-
placed sutures, and hemostasis was confirmed with direct
visualization of the closure site.
CONCLUSIONS
The MICHI Neuroprotection System employs large-
bore flow reversal with a transcervical approach and is
designed to provide a short and easy-to-use route for
delivery of interventional devices under optimized neuro-
protection. This first-in-man study suggests that this system
is safe and feasible to use for carotid stent placement.
Further studies will determine the role for FAST-CAS in
the treatment of patients with carotid artery stenosis at risk
for stroke. A larger, multicenter study is being planned to
confirm these outcomes.
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